Compare · DFTX vs OBIO
DFTX vs OBIO
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Orchestra BioMed Holdings Inc. (OBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and OBIO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $2.50B, about 10.4x OBIO ($241.3M).
- Over the past year, DFTX is up 190.6% and OBIO is up 20.5% - DFTX leads by 170.1 points.
- OBIO has been more active in the news (11 items in the past 4 weeks vs 3 for DFTX).
- OBIO has more recent analyst coverage (9 ratings vs 4 for DFTX).
PerformanceDFTX+190.56%OBIO+20.48%
2025-06-10+0.00%2026-06-09
- Company
- Definium Therapeutics Inc.
- Orchestra BioMed Holdings Inc.
- Price
- $22.94-0.35%
- $4.03+2.03%
- Market cap
- $2.50B
- $241.3M
- 1M return
- +3.94%
- -0.25%
- 1Y return
- +190.56%
- +20.48%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 3
- 11
- Recent ratings
- 4
- 9
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Latest OBIO
- Officer Hochman David P bought $19,150 worth of shares (5,000 units at $3.83), increasing direct ownership by 0.47% to 1,064,029 units (SEC Form 4)
- Officer Sherman Darren sold $58,050 worth of shares (15,000 units at $3.87) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 1,184,327 units (SEC Form 4)
- Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 144 filed by Orchestra BioMed Holdings Inc.
- Chief Financial Officer Taylor Andrew Lawrence covered exercise/tax liability with 3,076 shares, decreasing direct ownership by 0.49% to 629,417 units (SEC Form 4) (for tax liability)
- Officer Sherman Darren covered exercise/tax liability with 4,925 shares, decreasing direct ownership by 0.41% to 1,199,327 units (SEC Form 4) to satisfy tax liability
- Director Aryeh Jason bought $2,494 worth of shares (665 units at $3.75), increasing direct ownership by 0.57% to 118,118 units (SEC Form 4)
- Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
- Officer Hochman David P bought $18,850 worth of shares (5,000 units at $3.77), increasing direct ownership by 0.47% to 1,059,029 units (SEC Form 4)
- Director Aryeh Jason bought $34,987 worth of shares (8,971 units at $3.90), increasing direct ownership by 8% to 117,453 units (SEC Form 4)